There is a lot of anger and frustration among the shareholders. However if you see the history of this company and the possible future, the company is going through a transition phase. The pharma industry is very tough and they do not allow new companies to come and grow. Novavax has got the opportunity (through Covid) to make a transition from an experimental company (no revenue) to a product company (expected $B revenue). This is remarkable for a company who struggled for the last 35+ years and did not launch a product. Now is the perfect time to buy back (by the company) at least 10% of the share (costs ~670M) and lead the way for investors to get into ~$20B-$25B company. Many of the big investors will come forward as they start to see the revenue and the profit this year 2022. For a product company where manufacturing, quality, government/regulatory connections and experimental processes are already set, it will be quicker and easier to launch a new product into the market. On top of all, this company will be ready for other buyers to take over. Patience is the only key to come out of this transition wave. calm down is to strive for, calm down will rise!$Novavax(NVAX)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments